| Literature DB >> 26351512 |
Jeong Yong Moon1, Hyeonji Kim1, Somi Kim Cho2.
Abstract
The supercritical extraction method is a widely used process to obtain volatile and nonvolatile compounds by avoiding thermal degradation and solvent residue in the extracts. In search of phytochemicals with potential therapeutic application in gastric cancer, the supercritical fluid extract (SFE) of phalsak (Citrus hassaku Hort ex Tanaka) fruits was analyzed by gas chromatography-mass spectrometry (GC-MS). Compositional analysis in comparison with the antiproliferative activities of peel and flesh suggested auraptene as the most prominent anticancer compound against gastric cancer cells. SNU-1 cells were the most susceptible to auraptene-induced toxicity among the tested gastric cancer cell lines. Auraptene induced the death of SNU-1 cells through apoptosis, as evidenced by the increased cell population in the sub-G1 phase, the appearance of fragmented nuclei, the proteolytic cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP) protein, and depolarization of the mitochondrial membrane. Interestingly, auraptene induces an increase in the phosphorylation of Akt, which is reminiscent of the effect of rapamycin, the mTOR inhibitor that triggers a negative feedback loop on Akt/mTOR pathway. Taken together, these findings provide valuable insights into the anticancer effects of the SFE of the phalsak peel by revealing that auraptene, the major compound of it, induced apoptosis in accompanied with the inhibition of mTOR in SNU-1 cells.Entities:
Year: 2015 PMID: 26351512 PMCID: PMC4550746 DOI: 10.1155/2015/402385
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Cell viability on SNU-1 cells and GC-MS chromatogram of the SFEs of Jeju Citrus hassaku Hort ex Tanaka (phalsak). (a) Viability was determined on the basis of MTT reduction assay. (Data represent the means SD of at least four independent experiments. P < 0.01 indicate statistically significant differences versus control group.) (b) GC-MS chromatogram of SFEs. ((1) Auraptene standard peak, (2) SFE of phalsak peel, and (3) SFE of phalsak flesh; arrow indicates auraptene peak.)
Identification of compounds present in supercritical fluid extract of phalsak fruit by GC-MS.
| Namea | RTb | Peelc | Fleshc |
|---|---|---|---|
|
| 8.031 | 0.34 | — |
| 2-Octenal | 9.764 | — | 0.49 |
| Linalool | 10.957 | 0.69 | 0.85 |
| p-Menth-1-en-8-ol, (S)-(−)- | 13.776 | 1.39 | 0.41 |
| 2,4-Dimethylbenzaldehyde | 14.529 | — | 0.42 |
| 2-Ethylcyclohexanone | 15.299 | — | 0.34 |
| (E)-2-Decenal | 15.777 | — | 0.21 |
|
| 16.057 | 0.22 | — |
| (E,E)-2,4-Decadienal | 16.727 | 1.43 | 0.98 |
| Octadecyl vinyl ether | 17.885 | — | 0.13 |
| Citronellyl acetate | 18.321 | 0.28 | — |
| 2,4-Dimethyl-5-oxo-heptanal | 18.350 | — | 0.87 |
| Undec-2-enal | 18.654 | — | 0.28 |
| Geranyl acetate | 19.164 | — | 0.22 |
|
| 19.517 | 0.39 | — |
| Decylacetate | 19.853 | 0.27 | — |
| Limonen-10-yl acetate | 19.999 | 0.18 | — |
| trans-Caryophyllene | 20.373 | 0.10 | — |
| Perilla acetate | 20.646 | 0.13 | — |
| (E)-Geranylacetone | 21.049 | 0.16 | 0.16 |
| 3,7-Dimethyloct-1-en-3,7-diol | 21.146 | 0.52 | — |
| Oleic acid | 21.889 | — | 0.47 |
| 2,4-Di-tert-butylphenol | 22.610 | 0.28 | 0.4 |
| Sesquisabinene hydrate | 22.857 | 0.16 | — |
|
| 23.026 | 0.81 | — |
| Dihydroactinidiolide | 23.315 | 0.2 | 0.12 |
| Lauric acid | 23.822 | 0.38 | 0.33 |
| Nerolidol | 23.885 | 0.12 | — |
| (−)-Caryophyllene oxide | 24.645 | 0.40 | 0.17 |
| Diisobutylamine | 25.236 | — | 0.18 |
| Spathulenol | 25.681 | — | 0.21 |
|
| 27.172 | 0.13 | — |
| Duvatriendiol | 27.916 | 0.20 | — |
| Myristic acid | 28.487 | 0.28 | — |
| 6-Tridecen-6-al | 28.556 | 0.25 | — |
| (−)-Loliolide | 28.989 | 0.26 | — |
| N-Butylbenzenesulfonamide | 29.256 | 0.13 | 0.24 |
| Nootkatone | 29.93 | 5.83 | 0.15 |
| Platambin | 30.964 | 0.12 | — |
| Leden alkohol | 31.551 | 0.25 | — |
| Farnesyl acetone A | 31.922 | 0.31 | — |
| Methyl palmitate | 31.974 | — | 0.53 |
| Heptadecene-(8)-carbonic acid-(1) | 32.349 | 0.37 | — |
| 2-hydroxycyclopentadecan-1-one | 32.433 | — | 1.79 |
| Palmitic acid | 32.830 | 4.56 | — |
| Pentadecylic acid | 33.024 | — | 10.77 |
| Ethyl palmitate | 33.360 | — | 0.11 |
| Pentadecanoic acid, 14-bromo- | 34.216 | — | 0.2 |
| cis | 34.360 | — | 0.29 |
| 6-Tridecen-6-al | 34.730 | 0.36 | — |
| Manool | 34.985 | — | 0.37 |
| n-Nonadecane | 35.381 | — | 1.48 |
| Methyl oleate | 35.575 | 0.23 | — |
| Methyl linoleate | 36.248 | 3.61 | — |
| Heptadecene-(8)-carbonic acid-(1) | 36.403 | 3.46 | — |
| Oleic acid | 36.599 | — | 20.79 |
| Methyldiethylborane | 36.631 | 1.23 | — |
| N-Hentetracontanol-1 | 37.985 | — | 0.45 |
| n-Hexatriacontane | 39.026 | 2.43 | — |
| 3-Methylheptadecane | 40.266 | 1.53 | — |
| n-Hexatriacontane | 42.212 | 1.91 | — |
| n-Tetracosane | 43.068 | — | 0.69 |
| Auraptene | 44.453 | 20.77 | — |
| 2,2-Dimethyl-3-(3-methyl-5-phenylsulfanyl-pent-3-enyl)-oxirane | 45.903 | 3.98 | — |
| Lycopersen | 46.323 | 1.97 | 0.18 |
| trans-Caryophyllene | 48.047 | 0.22 | — |
| 3-Adamantan-1-yl-2-amino-propionic acid | 49.247 | — | 0.23 |
|
| 49.721 | 0.84 | — |
| Vitamin E | 49.755 | — | 0.21 |
| 4′,5,6,7,8-Pentamethoxyflavone | 50.677 | 1.29 | — |
|
| 51.344 | 3.51 | 2.14 |
| Stigmasterol | 51.768 | 1.80 | 0.67 |
| Obtusifoliol | 52.290 | 0.43 | 0.3 |
| 24- | 52.678 | — | 3.51 |
| Clionasterol | 52.714 | 6.34 | — |
| Fucosterol | 52.910 | — | 0.24 |
| 3,3′,4′,5,5′,7,8-Heptamethoxyflavone | 53.036 | 2.33 | — |
| 9,19-Cyclolanost-24-en-3-ol, acetate | 55.050 | — | 0.13 |
| Friedelan-3-one | 57.061 | 0.31 | — |
aSupercritical CO2 extract of fruit compounds tentatively identified based on retention index and elution order as well as the fragmentation pattern described in the literature.
bRetention time.
cRelative peak area percentage (peak area relative to the total peak area %).
Figure 2Cell growth inhibition by auraptene. Viability was determined on the basis of MTT reduction assay against various cancer cell lines and a noncancer cell line after treating with shown concentration of auraptene for 48 h. (Data represent the means SD of at least four independent experiments. P < 0.01 indicate statistically significant differences versus control group.)
Figure 3Nuclear Hoechst 33342 staining, cell cycle analysis, and determination of mitochondrial membrane potential. (a) Cells were treated with the indicated concentration of auraptene (25–100 μM) for 24 h and then stained with Hoechst 33342. Stained cells were visualized under a fluorescence microscope. (b) Mitochondrial membrane potential was determined by FACS caliber after being treated with given doses of auraptene. (Data represent the means SD of at least four independent experiments. P < 0.01 indicate statistically significant differences versus control group.)
The percentage of SNU-1 in each phase after treatment with auraptene for 24 h.
| Auraptene ( | ||||
|---|---|---|---|---|
| 0 | 25 | 50 | 100 | |
| Sub-G1 | 4.80 ± 1.36 | 7.34 ± 3.17 | 8.77 ± 4.45 | 23.45 ± 7.34 |
| G1 | 55.75 ± 0.91 | 61.34 ± 2.19 | 75.40 ± 6.40 | 51.36 ± 4.77 |
| S | 14.37 ± 0.67 | 12.08 ± 1.35 | 6.54 ± 1.49 | 10.36 ± 0.13 |
| G2/M | 25.59 ± 0.54 | 19.72 ± 3.41 | 9.65 ± 2.10 | 15.38 ± 3.28 |
Figure 4Western blot analysis of apoptosis and PI3K/Akt/mTOR related protein expression. (a) Cells were lysed after incubation with different concentrations of auraptene (25–100 μM). After 24 h, cell lysates were subjected to western blotting as mentioned in the method. (b) Western blotting for the effect of auraptene on Akt/mTOR related proteins in SNU-1 cells. (c) Cells were treated with rapamycin for 24 h in SNU-1 cells. β-actin was used as an internal control. (d) Cell growth inhibition by rapamycin. Viability was determined on the basis of MTT reduction assay against SNU-1 cells for 24 and 48 h. (Data represent the means SD of at least four independent experiments. P < 0.01 indicate statistically significant differences versus control group.)